Melasma including epidermal, dermal, and mixed types. Melasma Probiotics Chloasma Lactobacillus Bifidobacterium Skin pigmentation Skin erythema Skin texture Skin uniformity Wrinkles Photoaging
Conditions
Interventions
Topical probiotic culture filtrate lotion applied to the randomized side of the face affected by melasma. Participants will apply approximately 1 fingertip unit (about 0.2 to 0.4 g) as a thin layer ov
Experimental Drug,Placebo Comparator Drug
A lotion containing probiotics culture supernatant from Lactobacillus paracasei MSMC39-1 and Bifidobacterium animalis TA-1 ,Placebo
Sponsors
Professor Montree Udompataikul, MD
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Adults aged 18 years or older, of any sex. 2. Clinically diagnosed bilateral facial melasma with approximately symmetrical involvement on both sides of the face, confirmed by a dermatologist. 3. No chronic medical conditions that may interfere with study participation or affect study outcomes. 4. Willing and able to comply with study procedures and provide written informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or lactation. 2. Use of medications or treatments that may affect melasma within the preceding 12 weeks (washout period), including: topical or oral corticosteroids, skin-lightening agents (e.g., hydroquinone, arbutin, azelaic acid, kojic acid, tranexamic acid, resorcinol, vitamin C), agents that inhibit melanin transfer (e.g., soy, niacinamide), exfoliative agents (e.g., retinoids, AHA, BHA), agents that alter melanin synthesis (e.g., glutathione), antioxidants (e.g., vitamin C, vitamin E), cosmetic or dermatologic procedures such as chemical peeling, dermabrasion, mesotherapy, or laser treatment. 3. Presence of facial skin diseases that may interfere with assessment of the study area, including eczema, psoriasis, rosacea, severe or cystic acne, facial infection, inflammation, or contact dermatitis. 4. History of photosensitivity disorders, including autoimmune diseases, connective tissue disorders, or photodermatoses.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin pigmentation Weeks 0 (baseline), 4, 8, 12 after treatment modified MASI score | — |
Secondary
| Measure | Time frame |
|---|---|
| Skin parameter improvements including skin pigmentation, skin uniformity/texture, pore sizes, and wrinkles. Weeks 0 (baseline), 4, 8, 12 after treatment ANTERA 3D,Physician and patient global assessment scores Weeks 4, 8, 12 after treatment Physician and patient reported outcomes,Safety assessment Weeks 4, 8, 12 after treatment Recording of symptoms, date of event, date of report, grading, and description of event. | — |
Countries
Thailand
Contacts
Public ContactMontree Udompataikul
Department of Dermatology, Faculty of Medicine, Srinakharinwirot University
Outcome results
None listed